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Purpose: To conduct an economic evaluation comparing Ferinject® (ferric carboxymaltose 
[FCM]) with Venofer® (iron sucrose [IS]) and CosmoFer® (low-molecular-weight iron dextran 
[LMWID]) in the management of iron deficiency anemia in Greece.
Patients and methods: A cost-minimization analysis was conducted since there are no clear 
data indicating that one of these regimens is superior to the others in terms of efficacy. Main data 
inputs were based on bibliography and validated by clinicians. The economic evaluation was 
conducted for inpatients (ie, surgical patients or patients hospitalized due to a disease related to 
chronic or acute blood loss) and outpatients (eg, nondialysis chronic kidney disease patients), 
separately. Analysis was carried out from a National Health Service (NHS) perspective and 
also from a patient perspective. Total cost treatment reflects the cost of drugs, the cost of all 
resources expended in patient management such as the cost of disposables for each infusion, 
the monitoring costs during infusion (salaries of personnel), other hospital expenses, the cost 
for management of adverse events, the productivity loss, and the traveling cost for patients.
Results: In the case of outpatients, the mean total cost per patient in the FCM arm was €198.6, 
in the IS arm €627.7, and in the LMWID arm, €510.5. For inpatients the mean total cost was 
estimated at €189.2 for FCM while it was €419.9 and €228.8 for IS and LMWID, respectively. 
Budget impact analysis for a typical Greek hospital with 100 patients revealed that the total 
cost of FCM (inpatients analysis) was 113% and 15.4% lower against their comparators. In an 
outpatient situation, the total cost of FCM was 201.1% and 151.8% lower compared with IS 
and LMWID, respectively.
Conclusion: Ferric carboxymaltose may represent a cost-saving option compared with the 
most likely alternative existing therapies used for the management of anemia in the National 
Health Service of Greece.
Keywords: economic evaluation, cost minimization, ferric carboxymaltose, anemia, iron 
therapy
Introduction
Iron deficiency anemia (IDA) is a common and widespread disorder for adult men and 
women of different age bands, races, and ethnic groups.1 It has been estimated that in 
developed countries it occurs in 2%–5% of adult men and postmenopausal women and 
it represents a common cause of referral to gastroenterologists.2 The prevalence of IDA 
has been associated with conditions which cause chronic blood loss, such as inflam-
matory bowel disease, heavy uterine bleeding in postpartum women, and in chronic 
kidney disease.3–8 Its symptoms include fatigue, headache, dizziness, breathlessness, 
palpitations, and reduced cognitive function.7,8 In this context it can reduce patient 
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physical performance, ability to work, health-related quality 
of life (HR-QOL), and it may increase morbidity and 
mortality.7,8
Blood transfusion can elevate hemoglobin concentra-
tion in the short term, however it does nothing to address 
the underlying disorder and therefore despite its use there is 
still an unmet need. Moreover, in Greece and other countries 
there are often insufficient quantities to cover existing blood 
transfusion needs. In addition, blood donation is not free of 
risks, as it is often associated with infections and medical 
errors. Finally, this treatment is relatively expensive as the 
collection, storage, and use of blood comes at a cost.9,10
Thus, because of its convenience, availability and relative 
lower cost, oral iron represents a viable alternative treatment 
for anemia patients. Nonetheless, this treatment option too 
has some shortcomings and for this reason patients may 
also benefit from intravenous iron therapy. Specifically, 
ferric carboxymaltose (FCM; Ferinject®; Vifor Pharma, 
Wigan, UK), iron sucrose (IS; Venofer®; Vifor International 
Inc, Zurich, Switzerland) and low-molecular-weight iron 
dextran (LMWID; CosmoFer®; Pharmacosmos, Holbaek, 
Denmark) are commonly used intravenous (IV) iron therapies 
worldwide.11 The safety and efficacy, in terms of hemoglobin 
increase, of these agents is well documented in the literature 
and all three have been proven and deemed to be clinically 
equivalent.12–18 Nonetheless, they do not have the same mode 
of delivery and resource implications, and they also differ 
in terms of their price. Given that health care resources are 
scarce and must be spent wisely, a cost minimization analysis 
was undertaken to assess the above therapeutic alternatives 
in terms of their total treatment cost for the standard thera-
peutic course of 1000 mg in the Greek setting.19 The present 
paper presents the results of this economic analysis. This 
is particularly important at present. In the context of the 
financial crisis and the accompanying fiscal pressures, the 
memorandum signed with the International Monetary Fund, 
European Central Bank, and European Commission provides 
that pharmaceutical expenditure must be cut by 50% within a 
period of three years and total public health care expenditure 
must be maintained below 6% of GDP. Also patients are 
facing higher unemployment rates and lower income. Thus, 
an economic analysis may help to find ways to improve the 
economics of health care and assist patients.
Material and methods
Type and perspective of evaluation
Because treatments are equivalent in terms of effectiveness, 
a cost minimization analysis was undertaken. Thus only 
the total therapy cost of different options was evaluated. 
Because iron can be administered either in an inpatient 
setting (ie, surgical patients or patients hospitalized due 
to a disease related to chronic or acute blood loss) or in an 
outpatient setting (eg, nondialysis chronic kidney disease 
patients), the economic evaluation was conducted for these 
two large categories of patients, separately. The analysis 
was carried out from the perspective of the National Health 
Service (NHS) and also of patients. In the NHS perspective, 
health care costs associated directly with the medical care 
of patients were considered and they reflect the outpatient 
and inpatient management of patients respectively. From 
the patient perspective, transportation costs and productivity 
losses were accounted for.
Costing methodology
The total cost related to each treatment reflects the cost of 
drugs, the cost of disposables utilized in drug delivery, the 
monitoring cost of infusion, other hospital-related expenses, 
the management of adverse events, patient productivity loss, 
and patient traveling cost (Tables 1 and 2). Specifically, total 
drug cost is calculated as the product of total dose of 1000 mg 
(two units) and the drug price per unit. The prices of drugs 
used in the model are set in the last price bulletin issued by 
the Ministry of Commerce and are common across all public 
hospitals in Greece.20 Data regarding the disposables used 
for drug administration were based on expert advice. In 
particular, it was assumed that a serum device and a cannula 
were used per patient for each hospital visit. Furthermore, 
for inpatients, it was assumed that the average length of stay 
was 1 week. Thus, in the case of inpatient management, two 
additional visits for IS and none for LMWID and FCM were 
Table 1 Costing methodology used in the model
Parameter Direct cost computation
Total cost of drugs Number of units × cost per unit
Total cost of  
disposables
(Units of disposable per infusion × unit cost) × 
number of visits
Total monitoring cost 
True hospital cost
(Gross salary of doctor per month/ 
25 days/480 minutes/day + gross salary of 
nurse per month/25 days/480 minutes/day) × 
minutes of infusion × number of infusions 
(Total infusion hours/8 hours) × hospital 
cost × number of visits
Indirect cost computation
Total productivity loss Number of visits × (Gross domestic product 
per capita/300)
Total traveling cost Number of visits × traveling cost per visit
Notes: Disposable: cannula and serum device. in the case of inpatients, as “number 
of visits”, we have used the number of additional visits for infusion after patient 
discharge.
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assumed. In the case of outpatient management, five visits 
for IS and one for LMWID and FCM were assumed. In both 
options, the number of required visits per patient was based 
on expert advice combined with local average length of stay 
data to reflect the local management of anemia.
Monitoring cost reflects the time spent by staff to look after 
patients during administration and is based upon the salary per 
minute and the minutes expended by staff members to monitor 
infusions, and the number of corresponding visits. It must be 
noted that patients must be kept under close medical observa-
tion during the period of infusion. Regardless, personnel costs 
must be attributed to those treated in the hospital according to 
the time spent. This is also an opportunity cost. Hence, in the 
model it has been assumed that a doctor and a nurse should 
monitor patients during the IV infusion, according to local 
experts and summary of product characteristics (SPC).
Data concerning the time to infusion were collected from 
the SPCs21–23 and were verified by local experts. Based on 
expert opinion, the average time spent on LMWID infusion 
was set at 8 hours in total, even though it is acknowledged 
that in some settings 1000 mg can be given over 5 hours.24 For 
similar reasons, for IS the total amount of care (preparation, 
infusion, post-therapy monitoring) is set at 10 hours.
The hospital cost quantifies the remaining operating 
and overhead cost for accommodating a patient during the 
  infusion. Thus, this type of cost is linearly related to the time 
spent for the infusion. Based on data gathered by the National 
School of Public Health on behalf the Ministry of Health 
across the country, the hospital operating and overhead cost 
(excluding personnel and drugs) was estimated at €280 for 
a normal morning hospital shift, on average.
The management of adverse events reflects expenses for 
the treatment of headache, dizziness, constipation, nausea, 
vomiting, diarrhea, abdominal pain, injection site reactions, 
fatigue, pyrexia, chest pain, rash, muscle cramp, back 
pain, dyspnea, and cough, which are commonly reported 
adverse events and are similar amongst comparators.25 
Productivity loss reflects the foregone production due to 
missed days of work in order to receive the treatment or due 
to anaphylactic reactions in patients receiving LMWID. It 
may be an underestimate as in some cases patients may 
be accompanied by family members and thus productivity 
loss is higher. It must be noted that hospitalized patients 
are not incurring any productivity loss in our analysis. 
Furthermore it is assumed that in the case of IS a day of 
work is lost due to travelling, treatment delivery, post-
treatment monitoring, and hospital administration and 
waiting time.
This indirect cost per day is calculated in terms of the 
gross domestic product per capita divided by the number 
of working days per year.26 In the case of LMWID, it was 
assumed that delayed anaphylactic reactions impose 2 days 
absence of work for recovery without hospitalization in the 
case of 15% of patients.27,28
Traveling cost reflects the expenses of patients for travel-
ing to and from the hospital. In Greece almost all patients 
reach hospitals for IV infusion by using public or private 
transport facilities. The mean cost per visit was obtained from 
the literature, where the mean traveling cost per patient visit 
has been estimated at €40.29 In a similar manner, the total 
traveling cost is calculated by multiplying the travel cost for 
each visit by the number of visits.
Table 2 Cost per item used in the model
Cost of drugs* Cost (€) per unit Total number of units
Inpatients Outpatients
Cosmofer (5 amp × 100 mg) 28.48 2 2
Venofer (5 amp × 100 mg) 31.64 2 2
Ferinject (5 amp × 100 mg) 85.93 2 2
Cost for personnel time Cost (€) per hour** Needed hours Needed hours
Doctor/nurse €11.50/€6.50
Cosmofer 8 8
Venofer 10 10
Ferinject 0.25 0.25
Number of additional visits Cost (€) per visit**
Cosmofer 280.00 0 1
Venofer 280.00 2 5
Ferinject 280.00 0 1
Disposables per visit Cost (€) per unit Units per infusion Units per infusion
Serum device 0.36 1 1
Cannula 0.40 1 1
Notes: *Price Bulletin; **National School of Public Health.
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Uncertainty
To deal with uncertainty, probability distributions were speci-
fied around all of the main analysis parameters. Specifically, 
probabilistic variables for the time infusion, transportation 
cost and productivity loss were associated with normal dis-
tributions around the mean and a 10% coefficient of variation 
(CV). Bias-corrected uncertainty intervals (UI) of costs have 
been calculated using the percentile method of nonparametric 
bootstrapping (using 1000 replications).30 It is important to 
indicate that, given the probabilistic nature of all compo-
nents, the cost of each comparator can be slightly different 
in each bootstrap experiment. Nonetheless, the bootstrapped 
costs follow a normal distribution based on the central limit 
theorem.31 In addition a supplementary one-way sensitivity 
analysis was conducted. Hence, the cost of drugs and the 
main cost components were varied at ±20% to examine the 
stability of results under different assumptions.
Budget impact
A supplementary budget impact analysis was conducted in 
order to estimate the budget impact of specific utilization 
scenarios. As mentioned in the introduction, this is important 
as drug and health care budgets must be reduced over time. 
The objective was to assess the economic impact within 
a 1-year time horizon. Hence, the results presented below 
refer to the total cost of 12 months’ use of each therapy for 
a hypothetical cohort of 100 patients. It is straightforward 
to compute the economic benefit (loss) from a decision to 
use different therapies.
Results
Results are shown in Table 3. In particular, in the outpatient 
setting the direct therapy cost per patient in the FCM arm 
was €198.6 (95% UI: €194.3–€204.2), in the IS arm was 
€627.7 (95% UI: €587.9–€675.8), while in the LMWID 
arm was €510.5 (95% UI: €465.4–€560.5). Thus, the direct 
cost in the FCM group was the lowest, with a mean dif-
ference of €429.1 (95% UI: €390.1–€477.8) and €311.9 
(95% UI: €268.7–€359.2) in relation to IS and LMWID, 
respectively.
The mean traveling cost for patients in FCM was €40.4 
(95% UI: €33.9–€48.1) against €202 (95% UI: €169.6–€240.7)   
and €40.4 (95% UI: €33.9–€48.1) for IS and LMWID, 
respectively. The productivity loss was estimated at €73.3 
(95% UI: €39.7–€128.2) in the case of FCM, while it was 
€366.7 (95% UI: €212.5–€580.2) in the case of IS and €96 
(95% UI: €65.2–€138.7) for LMWID. The main item driving 
the direct cost in the FCM arm was the cost of medication 
Table 3 Total cost and cost components per treatment arm
Mean (95% LUI–95% UUI) FCM IS LMWID
Outpatient
Direct cost (€)
  Drugs 171.9 (n/a) 63.3 (n/a) 57 (n/a)
  Adverse events 12.4 (8.4–18) 12.4 (8.4–18) 12.4 (8.4–18)
  Disposables 0.8 (0.5–1.1) 3.8 (3.5–4.1) 0.8 (0.5–1.1)
  Monitoring 4.8 (3.8–6) 197.7 (176–219.6) 159.9 (125.1–196)
  Hospital cost 8.8 (7.9–9.8) 350.5 (315.1–392.6) 280.4 (252.1–314.1)
  Total direct cost 198.6 (194.3–204.2) 627.7 (587.9–675.8) 510.5 (465.4–560.5)
Other costs (€)
  Productivity loss 73.3 (39.7–128.2) 366.7 (212.5–580.2) 96 (65.2–138.7)
  Traveling cost 40.4 (33.9–48.1) 202 (169.6–240.7) 40.4 (33.9–48.1)
  Total other costs 113.7 (73.6–176.3) 568.7 (382–820.9) 136.4 (99.1–186.9)
Inpatient
Direct cost (€)
  Drugs 171.9 (n/a) 63.3 (n/a) 57 (n/a)
  Adverse events 12.5 (8.7–17.7) 12.5 (8.7–17.7) 12.5 (8.7–17.7)
  Disposables 0 (n/a) 1.5 (1.2–1.8) 0 (n/a)
  Monitoring 4.8 (3.8–5.9) 197.5 (177.3–220.4) 159.3 (126–195.6)
  Hospital cost 0 (n/a) 140 (125.9–156.1) 0 (n/a)
  Total direct cost 189.2 (185.1–194.4) 414.9 (388.7–442.7) 228.8 (194.1–265.2)
Other costs (€)
  Productivity loss 0 (n/a) 144.5 (86.3–225.7) 22.7 (17.7–28)
  Traveling cost 0 (n/a) 80.1 (66.6–95.6) 0 (n/a)
  Total other costs 0 (n/a) 224.7 (152.9–321.3) 22.7 (17.7–28)
Notes: Based on 1000 bootstrap replications.
Abbreviations: LUi, lower uncertainty interval; UUi, upper uncertainty interval; FCM, ferric carboxymaltose; iS, iron sucrose; LMWiD, low-molecular-weight iron dextran.
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(86.5%), while the monitoring cost and the hospital operat-
ing and overhead cost was substantially lower compared 
to other agents due to the different delivery mode. These 
figures are important as average monthly income for many 
workers has fallen by around €500 to €700 as a result of the 
financial crisis.
For inpatients, the mean direct cost of therapy in the FCM 
arm was €189.2 (95% UI: €185.1–€194.4), in the IS arm it was 
€414.9 (95% UI: €388.7–€442.7), while in the LMWID arm 
it was €228.8 (95% UI: €194.1–€265.2). As with the previ-
ous findings, the mean total treatment cost in the FCM group 
was the lowest, with a mean reduction of €225.7 (95% UI: 
€200.2–€252.2) and €39.6 (95% UI: €6.6–€75.7) relative to 
IS and LMWID, respectively. FCM is characterized by an 
absence of productivity loss or traveling cost in this scenario. 
By contrast, in the case of IS, productivity loss was estimated at 
€144.5 (95% UI: €86.3–€225.7), while it was €22.7 (95% UI: 
€17.7–€28.0) in the case of LMWID. The traveling cost was 
estimated at €80.1 (95% UI: €66.6–€95.6) in the case of IS.
Budget impact
Budget impact analysis takes into account the budget impli-
cations for hospitals. Despite the fact that FCM has a higher 
price compared to the other treatments it is the least costly 
option to use (Figure 1). Overall, per annum the treatment 
of 100 patients on an outpatient basis amounts to €19,787, 
against €61,358 and €49,822 for IS and LMWID respectively, 
delivering corresponding savings of up to 210% and 152% 
respectively. Similarly, overall per annum, treatment of 100 
patients on an inpatient basis totals €18,836, against €40,130 
and €21,746 for IS and LMWID respectively, delivering 
corresponding savings of 113% and 15%.
Sensitivity analysis
Results from a one-way sensitivity analysis are presented 
in Table 4, where the main input parameters of the model 
such as the cost of drugs, the gross salaries of personnel and 
the number of visits are altered within a ±20% range. This 
analysis indicates that FCM remains an attractive option 
relative to other therapies in the majority of sensitivity 
analyses. The results are highly sensitive only to the cost 
of drugs, which however are deterministic. It must be noted 
that deterministic results are slightly different from the mean 
bootstrap results due to correction bias term incorporated in 
the probabilistic analysis.
Discussion
Anemia is a fairly common condition, affecting both men 
and women of all ages, races and ethnic groups. Anemia is 
frequently caused by iron deficiency, which is associated 
with a variety of coexisting conditions. Patients with anemia 
may benefit from iron therapy. Although oral iron is the treat-
ment of choice for the majority of the patients because of its 
effectiveness, safety, and cost, oral iron has disadvantages, 
including poor compliance, high incidence of adverse gas-
trointestinal effects and high potential for interactions with 
other treatments. Therefore, parenteral administration of iron 
(ie, intravenous iron) has been introduced in clinical practice. 
FMC, IS, and LMWID are the main available intravenous 
IV iron forms, in Greece and elsewhere.
IS FCM
�0
�10.000
�19.787 �18.836
�61.358
�40.130
�49.822
�21.746
�20.000
�30.000
�40.000
�50.000
�60.000
�70.000
LMWID
Outpatients Inpatients
Figure 1 Budget impact analysis per year for a cohort of 100 patients.*
Note: *Assuming 100% substitution rate amongst comparators.
Abbreviations: FCM, ferric carboxymaltose; iS, iron sucrose; LMWiD, low-molecular-weight iron dextran.
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In the present study, a comparison of the cost among 
FMC, IS and LMWID, was undertaken using a probabilis-
tic model. The comparison was conducted on an inpatient 
and outpatient basis from an NHS and patient perspective 
in Greece. According to the results, FMC may represent a 
cost-saving option, as it is associated with a lower total cost. 
Sensitivity analysis showed that the main results were robust. 
The main item driving the direct cost in the FMC arm was the 
cost of drugs. In the case of IS and LMWID, the monitoring 
and hospital costs were substantially higher due to the dif-
ferent delivery mode, which required a substantial amount 
of time for each infusion.
It must be noted that little is known about the impact of 
anemia on health care utilization and costs in general,32–34 and 
economic evaluations amongst comparators are rare in the 
literature. The results of the current study are in agreement 
with those reported in a similar one undertaken from a health 
care payer’s perspective in Switzerland. In this study, it was 
found that treating patients with iron deficiency anemia with 
FMC instead of IS reduced the cost per treatment cycle by 
35% in patients with inflammatory bowel disease (empirical 
dose 1000 mg of iron) and by 33% in patients with gyne-
cological indications (empirical dose 500 mg of iron).35 In 
another study, the aim was to evaluate the health care costs 
of IS and FMC treatment in patients with inflammatory 
bowel disease in an outpatient setting. The study concluded 
that FCM represents a cost-effective choice in Denmark.36 
Furthermore, it has been argued that FCM reduces waiting 
time and waiting list pressure, and also reduces consumables 
and hospital transport costs.37 Similar conclusions were 
obtained in a study undertaken in Spain, where in a popula-
tion with preoperative anemia treatment the total cost of 
FMC was estimated at €244 versus €307 for IS.38 A recent 
study undertaken in the UK on outpatients has found that 
FCM represents a cost-saving option compared to IS but it 
is more costly than LMWID.24 However, this difference may 
be attributed to the different methodologies, assumptions and 
unit price data utilized in the two studies, in order to reflect 
local practice properly.
The analysis pursued suffers from drawbacks and 
limitations, which are common in studies using similar 
  methodologies. It does not represent experimental research, 
but instead it is based on an economic model using data 
reported in the literature, and on various assumptions, and thus 
it may suffer from biases. In order to limit possible sources of 
bias, standard recommendations were followed. Thus, a sys-
tematic review and assessment of the evidence was performed 
and stochastic analysis was used to deal with uncertainty. 
This methodology cannot substitute for real-ife comparisons; 
however the present model represents a reasonable alterna-
tive approach and its assumptions are based on data from 
published studies in the literature and medical practice and 
are easy to handle. The results must also be considered in the 
Greek setting only and on the basis of current resources and 
drug prices. If any of the underlying parameters change, so 
may the results and the conclusions of the analysis. Finally, 
we confined the analysis to the health care and patient per-
spective and not to society overall. A broader analysis could 
be the scope of additional research in the future.
Conclusion
In Greece, health care and pharmaceutical budgets are 
being cut, disposable income is shrinking, and at the same 
time unemployment is increasing. Thus, we undertook an 
Table 4 Total cost per treatment arm* based on one-way sensitivity analysis for the main model parameters
-20% 20% (-20%) (+20%)
FMC IS LMWID FMC IS LMWID
Inpatients
Cost per drug unit for FMC 68.7 103.1 €154.0 €401.3 €217.0 €222.7 €401.3 €217.5
Gross salary per month (Doctor) 1,840.0 2,760.0 €187.8 €377.7 €198.5 €188.9 €424.9 €236.4
Gross salary per month (Nurse) 1,040.0 1,560.0 €188.0 €388.0 €206.8 €188.7 €414.6 €228.2
Additional visits (for iS) 1 3 €188.4 €330.5 €217.5 €188.4 €472.0 €217.5
Cost per visit 224.0 336.0 €188.4 €401.3 €217.5 €188.4 €401.3 €217.5
Outpatients
Cost per drug unit for FMC 68.7 103.1 €163.5 €613.6 €498.2 €232.3 €613.6 €498.2
Gross salary per month (Doctor) 1,840 2,760 €197.3 €519.3 €479.3 €198.5 €566.4 €517.2
Gross salary per month (Nurse) 1,040 1,560 €197.5 €529.5 €487.5 €198.2 €556.2 €509.0
Additional visits (for iS) 4 6 €197.9 €542.8 €498.2 €197.9 €684.3 €498.2
Cost per visit 224.0 336.0 €196.1 €613.6 €442.2 €199.6 €613.6 €554.2
Note: *Only direct cost was considered.
Abbreviations: FCM, ferric carboxymaltose; iS, iron sucrose; LMWiD, low-molecular-weight iron dextran.
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economic evaluation comparing alternative therapies for 
anemia management. Ferric carboxymaltose may represent a 
cost-saving option compared with the other likely alternative 
existing therapies used for the management of anemia in the 
National Health Service of Greece at present.
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